Related Experiment Videos
Lymphocyte apoptosis in ovariectomized mice given progesterone and voluntary exercise
1Department of Health Studies and Gerontology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. lhgoetz@healthy.uwaterloo.ca
The Journal of Sports Medicine and Physical Fitness
|October 23, 2002
Summary
Progesterone replacement in ovariectomized mice did not change running behavior. However, progesterone alone slightly increased spleen cell apoptosis, highlighting the need for further research on its clinical relevance for postmenopausal women.
Area of Science:
- Reproductive Endocrinology
- Immunology
- Exercise Physiology
Background:
- Menopausal hormone replacement therapy (HRT) and exercise are common, but progesterone's effects are less understood.
- Estrogen's impact on exercise and immunity is known, but progesterone's specific consequences require investigation.
- This study examines progesterone's influence on running behavior and immune cell viability in mice.
Purpose of the Study:
- To determine the effect of progesterone on running behavior in ovariectomized mice.
- To assess progesterone's impact on lymphoid tissue cell viability and apoptosis.
- To understand the behavioral and immunological consequences of progesterone administration.
Main Methods:
- Ovariectomized female mice received progesterone or placebo pellets for 21 days.
- Mice were assigned to running wheel or sedentary conditions.
- Flow cytometry analyzed thymocyte and splenocyte apoptosis, necrosis, and viability.
Main Results:
- Progesterone-treated mice showed increased body weight compared to controls.
- Running activity increased over time, irrespective of hormone treatment.
- Progesterone marginally increased spleen cell apoptosis and reduced viability, with no effect on thymus cells.
Conclusions:
- Progesterone replacement did not alter running volume in ovariectomized mice.
- Progesterone administration was linked to a minor increase in splenocyte apoptosis.
- The clinical significance of these lymphocyte viability changes for postmenopausal women warrants further investigation.